Myelofibrosis medical therapy

Revision as of 17:32, 26 August 2015 by Jyostna Chouturi (talk | contribs)
Jump to navigation Jump to search

Myelofibrosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myelofibrosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myelofibrosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myelofibrosis medical therapy

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myelofibrosis medical therapy

CDC on Myelofibrosis medical therapy

Myelofibrosis medical therapy in the news

Blogs on Myelofibrosis medical therapy

Directions to Hospitals Treating Myelofibrosis

Risk calculators and risk factors for Myelofibrosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical therapy

Other treatment options are largely supportive, and do not alter the course.[1] These options may include regular folic acid, allopurinol or blood transfusions. Dexamethasone, alpha-interferon and hydroxycarbamide may play a role.

Lenalidomide and Thalidomide may be used in its treatment, though they can cause gout and leave the patient susceptible to diseases such as pneumonia.

Frequent blood transfusions may also be required.

The patient with the myelofibrosis should be tested for Tuberculosis even if the patient doesn't manifest the symptoms of TB. There is strong evidence of myelofibrois improvement with the antituberculous treatment.

References

  1. Kröger N, Mesa RA (2008). "Choosing between stem cell therapy and drugs in myelofibrosis". Leukemia. 22 (3): 474–86. doi:10.1038/sj.leu.2405080. PMID 18185525. Unknown parameter |month= ignored (help)


Template:WikiDoc Sources